Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

PURPOSE: To evaluate the safety and tolerability of subcutaneous IgPro20 (Hizentra(®), CSL Behring, King of Prussia, PA, USA) administered at high infusion parameters (> 25 mL and > 25 mL/h per injection site) in patients with primary immunodeficiency. METHODS: The Hizentra(®) Label Optimizati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Immunol
Main Authors: Anderson, John T., Bonagura, Vincent R., Cowan, Juthaporn, Hsu, Connie, Mustafa, S. Shahzad, Patel, Niraj C., Routes, John M., Sriaroon, Panida, Vinh, Donald C., Hofmann, Jutta H., Praus, Michaela, Rojavin, Mikhail A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7858210/
https://ncbi.nlm.nih.gov/pubmed/33409867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-020-00912-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados